China Approves World's First Invasive Brain-Computer Interface for Clinical Use

A Landmark Regulatory Approval

China's National Medical Products Administration (NMPA) has officially approved the registration application for the NEO Brain-Computer Interface System. This marks a historic global first, as an invasive neurotechnology device has finally transitioned from experimental laboratory trials to legitimate clinical application. Developed by Neuracle Technology in collaboration with Tsinghua University, the system is specifically designed to assist patients with quadriplegia caused by cervical spinal cord injuries.

The Goldilocks of Neurotechnology

The NEO system is unique because it utilizes a semi-invasive epidural approach. Unlike fully invasive chips that penetrate brain tissue and risk long-term scarring, this device sits on the protective layer outside the brain. The coin-sized implant is placed into a small groove milled into the skull, ensuring high signal quality without direct contact with delicate cerebral tissue. This design offers a safer, more stable solution for long-term home use than many competing technologies.

Restoring Independence Through Thought

Patients using the system can control a pneumatic robotic glove through thought alone. The device captures neural signals from the motor cortex and transmits them wirelessly to the external glove, effectively bypassing damaged sections of the spinal cord. This enables paralyzed users to perform essential daily tasks such as gripping a glass or picking up objects. The entire system operates without internal batteries, relying on wireless power transfer to minimize the risk of infection.

Leading the Global Race

This approval places China at the forefront of the global neurotechnology race. By securing regulatory clearance, Neuracle Technology has moved faster than prominent international competitors such as Neuralink and Synchron. The milestone aligns with China's strategic designation of brain-computer interfaces as a priority future industry, supported by a growing ecosystem of dozens of innovative enterprises based in Shanghai and beyond.

Proven Clinical Results

During extensive clinical trials, participants reported significant improvements in independence within just one month of the surgical procedure. One notable case involved a patient who achieved over 90 percent accuracy in grasping tasks after losing mobility in a car accident. The surgery is remarkably efficient, typically taking less than two hours and utilizing advanced positioning systems that do not require the patient to remain awake. More information on this breakthrough can be found at AASTOCKS.